Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000241 · ClinicalTrials.gov registry record · Phase 2
Flupenthixol Decanoate in Methamphetamine Smoking - 1
A Phase 2 study of Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00000241 is a Phase 2 study of Substance-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 58 participants, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00000241, a Phase 2 study of Substance-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.
Conditions Studied
Interventions
- DRUG Flupenthixol
Study Locations (1)
California
- Friends Research Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1994-02 |
| Est. Completion | 1996-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000241
The ClinicalTrials.gov registry entry for NCT00000241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Flupenthixol is the first listed.
NCT00000241 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00000241 about?
NCT00000241 is a clinical study titled "Flupenthixol Decanoate in Methamphetamine Smoking - 1". The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.
What is the current status of trial NCT00000241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 1994-02. Estimated completion is 1996-05.
What conditions does trial NCT00000241 study?
This clinical trial studies the following conditions: Substance-Related Disorders.
What interventions are being tested in trial NCT00000241?
The interventions under investigation include: Flupenthixol (DRUG).
Who is sponsoring clinical trial NCT00000241?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000241 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
A Laboratory Model for Heroin Abuse Medications - 8
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.